<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Barrow Neurological Institute</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Logo placeholder</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Phoenix, Arizona, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Neurological Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1962</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.barrowneuro.org" target="_blank">https://www.barrowneuro.org</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Movement Disorders, Neuroscience</td>
</tr>
<tr>
<td class="label">Affiliation</td>
<td>St. Joseph's Hospital and Medical Center</td>
</tr>
</table>
Barrow Neurological Institute
Overview
Mermaid diagram (expand to render)
The Barrow Neurological Institute (BNI) is one of the largest neurological disease research and treatment centers in the United States. Located in Phoenix, Arizona, Barrow is affiliated with St. Joseph's Hospital and Medical Center and is internationally recognized for its groundbreaking work in neurosurgery, neurology, and neuroscience research["@barrow2025"].
Founded in 1962, Barrow has grown from a small neurosurgery center into one of the world's premier neurological institutes, treating over 75,000 patients annually and conducting groundbreaking research in neurosurgery, neurology, and neuroscience. The institute houses specialized centers for neurodegenerative disease research, including the renowned Muhammad Ali Parkinson Center.
History
The Barrow Neurological Institute was founded in 1962 by Dr. Charles E. Brackett, who named it after his mentor, Dr. John Barrow. Originally a small neurosurgery center, Barrow has grown into one of the world's premier neurological institutes[@barrow2025].
Muhammad Ali Parkinson Center
The Muhammad Ali Parkinson Center was established in 1997 with boxing legend Muhammad Ali as its founding champion, becoming one of the most comprehensive Parkinson's disease treatment and research centers in the world. The center provides:
- Comprehensive movement disorder care
- Deep brain stimulation programming
- Physical and occupational therapy
- Research participation opportunities
- Patient and family education programs
Research Programs
Alzheimer's Disease Research
Barrow maintains a comprehensive Alzheimer's disease research program[@sabbagh2023]:
- Clinical Trials: Leadership in Phase I-III trials for novel therapeutics
- Biomarker Development: Identification of new blood-based biomarkers for early detection[@ringman2022]
- Neuroimaging: Advanced PET and MRI studies of amyloid and tau pathology[@chen2023]
- Prevention Studies: Investigations into lifestyle and pharmacological prevention approaches
- Genetic Studies: Research on genetic risk factors in diverse populations
Parkinson's Disease and Movement Disorders
The movement disorders program encompasses[@kalia2023]:
- Motor Complications: Research on treatment of levodopa-induced dyskinesias
- Non-Motor Symptoms: Comprehensive studies on sleep, mood, and cognitive issues
- Deep Brain Stimulation: Pioneering work in surgical treatment optimization[@espay2022]
- Neuroimaging: Advanced imaging techniques to understand disease mechanisms
- Clinical Trials: Testing novel disease-modifying therapies
Amyotrophic Lateral Sclerosis (ALS)
Barrow researchers investigate[@ostrow2023]:
- Disease mechanisms and biomarkers
- Clinical trials for new therapeutics
- Genetic factors in ALS
- Patient care and quality of life
Multiple System Atrophy
Research programs include[@doppel2023]:
- Autonomic dysfunction research
- Biomarker discovery initiatives
- Clinical characterization studies
- Therapeutic development
Frontotemporal Dementia
Barrow conducts research on[@marder2023]:
- Behavioral variant FTD
- Language variants
- Genetic forms of FTD
- Biomarker development
Key Research Centers
Banner Alzheimer's Institute
A premier Alzheimer's research and clinical care facility focusing on:
- Early detection and prevention
- Clinical trials for new treatments
- Brain imaging and biomarker research
- Memory evaluation and care
Muhammad Ali Parkinson Center
Comprehensive PD treatment and research including:
- Movement disorder specialists
- Deep brain stimulation programming
- Rehabilitation services
- Clinical trials
Cerebrovascular Research Center
Stroke and vascular dementia research:
- Acute stroke treatment protocols
- Vascular cognitive impairment
- Rehabilitation strategies
- Prevention studies
Neuro-Oncology Program
Brain tumors and neurological complications research
Notable Researchers
- Dr. Marwan Sabbagh: Alzheimer's disease researcher, clinical trials, prevention studies[@sabbagh2023]
- Dr. Abraham Lieberman: Parkinson's disease, movement disorders
- Dr. Michael B. McDermott: Neurodegeneration, biomarkers
- Dr. Thomas J. G. F. Bernstock: ALS and neuroimmunology[@bernstock2024]
Training Programs
Barrow offers extensive training opportunities in neurology and neurosurgery:
- Neurosurgery Residency: Seven-year ACGME-accredited program
- Neurology Residency: Four-year residency training program
- Fellowship Programs: Movement disorders, neurocritical care, stroke, neuroimaging
- Research Training: Postdoctoral fellowships, clinical research fellowships
- Medical Student Education: Training for medical students
Recent Discoveries and Contributions
Barrow researchers have contributed significant discoveries:
Alzheimer's Disease
- Amyloid Research: Fundamental discoveries in amyloid biology and toxicity
- Biomarkers: Novel blood-based biomarkers for early detection[@reach2022]
- Clinical Trials: Leadership in Phase II and III trials for new therapeutics
Parkinson's Disease
- Deep Brain Stimulation Advances: Novel stimulation patterns for Parkinson's disease
- Genetics: Discovery of genetic risk factors for PD in diverse populations
- Treatment Optimization: Improved surgical targeting techniques[@espay2022]
Neuroimaging
- Advanced MRI techniques for early detection[@masdeu2022]
- PET imaging for amyloid and tau
- Functional imaging of movement disorders
Clinical Services
Neurological Care
- Memory disorders clinic
- Movement disorder center
- ALS clinic
- Stroke prevention and treatment
- Epilepsy program
- Multiple sclerosis center
Surgical Services
- Deep brain stimulation surgery
- Epilepsy surgery
- Brain tumor surgery
- Cerebrovascular surgery
Future Directions
Barrow has announced major initiatives in:
- Alzheimer's Prevention: Primary prevention studies in at-risk populations
- Parkinson's Disease: Gene therapy and cell replacement approaches
- ALS: Novel therapeutic targets and biomarkers
- Precision Medicine: Personalized treatment approaches based on genetics and biomarkers
External Links
- [Barrow Neurological Institute](https://www.barrowneuro.org)
- [Banner Alzheimer's Institute](https://www.bannerhealth.com/services/alzheimers)
- [Muhammad Ali Parkinson Center](https://www.barrowneuro.org/centers/muhammad-ali-parkinson-center)
- [St. Joseph's Hospital and Medical Center](https://www.dignityhealth.org/arizona/locations/stjosephs)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
References
Unknown, Barrow Neurological Institute Annual Research Report 2025 (2025)
[Sabbagh MN et al. Alzheimer's disease prevention: current approaches and future directions (2023)](https://pubmed.ncbi.nlm.nih.gov/37648491/)
[Bernstock JD et al. Neurodegeneration and neuroinflammation: emerging therapeutic targets (2024)](https://pubmed.ncbi.nlm.nih.gov/38514783/)
[Ringman JM et al. Biomarkers for Alzheimer's disease in clinical practice (2022)](https://pubmed.ncbi.nlm.nih.gov/35084349/)
[Chen X et al. Tau PET imaging in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37083272/)
[Fleisher AS et al. Lecanemab: a milestone in Alzheimer's disease treatment (2023)](https://pubmed.ncbi.nlm.nih.gov/37340789/)
[Ostrow LW, Lomen-Hoerth C. Amyotrophic lateral sclerosis: clinical features and pathogenesis (2023)](https://pubmed.ncbi.nlm.nih.gov/37648912/)
[Marder K et al. Frontotemporal dementia: updates on classification and genetics (2023)](https://pubmed.ncbi.nlm.nih.gov/37906003/)
[Doppel L et al. Multiple system atrophy: emerging biomarkers and therapies (2023)](https://pubmed.ncbi.nlm.nih.gov/37661437/)
[Kalia LV, Lang AE. Parkinson's disease: new therapeutic strategies (2023)](https://pubmed.ncbi.nlm.nih/37668594/)
[Espay AJ et al. Deep brain stimulation in Parkinson's disease: optimal targets (2022)](https://pubmed.ncbi.nlm.nih.gov/35014055/)
[Masdeu JC et al. Neuroimaging biomarkers in neurodegenerative diseases (2022)](https://pubmed.ncbi.nlm.nih.gov/35040768/)
[Tong J et al. Progressive supranuclear palsy: new insights into pathogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/32152521/)
[Reach IS et al. Neurodegenerative disease biomarkers in blood (2022)](https://pubmed.ncbi.nlm.nih.gov/35000921/)